There is considerable interest in quantifying anti-PEG
antibodies,
given their potential involvement in accelerated clearance, complement
activation, neutralization, and acute reactions associated with drug
delivery systems. Published and commercially available anti-PEG enzyme-linked
immunosorbent assays (ELISAs) differ significantly in terms of reagents
and conditions, which could be confusing to users who want to perform
in-house measurements. Here, we optimize the ELISA protocol for specific
detection of anti-PEG IgG and IgM in sera from healthy donors and
in plasma from cancer patients administered with PEGylated liposomal
doxorubicin. The criterion of specificity is the ability of free PEG
or PEGylated liposomes to inhibit the ELISA signals. We found that
coating high-binding plates with monoamine methoxy-PEG5000, as opposed to bovine serum albumin-PEG20000, and blocking
with 1% milk, as opposed to albumin or lysozyme, significantly improve
the specificity, with over 95% of the signal being blocked by competition.
Despite inherent between-assay variability, setting the cutoff value
of the optical density at the 80th percentile consistently identified
the same subjects. Using the optimized assay, we longitudinally measured
levels of anti-PEG IgG/IgM in cancer patients before and after the
PEGylated liposomal doxorubicin chemotherapy cycle (1 month apart,
three cycles total). Antibody titers did not show any increase but
rather a decrease between treatment cycles, and up to 90% of antibodies
was bound to the infused drug. This report is a step toward harmonizing
anti-PEG assays in human subjects, emphasizing the cost-effectiveness
and optimized specificity.